Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
Novo Nordisk, a pioneering maker of obesity drugs, has made headlines with the announcement that chief executive Lars Fruergaard Jørgensen will be stepping down. This news comes just days after the company cut its profit forecast, causing concern among investors.
In a statement released on Friday, Novo Nordisk stated that they have initiated the search for a new chief executive, citing the need for new leadership in light of recent market challenges and a decline in the company’s share price. The decision to part ways with Jørgensen was reached collaboratively between the Novo Nordisk Board, the Novo Nordisk Foundation, and Jørgensen himself.
“Considering the recent market challenges, the share price decline and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that initiating a CEO succession is in the best interest of the company and its shareholders,” Novo Nordisk stated.
As this story continues to develop, it will be interesting to see how Novo Nordisk navigates this leadership transition and what impact it will have on the company’s future direction and performance.
Stay tuned for more updates on this breaking news story.
